People: NewLink Genetics Corp (NLNK.W)
NLNK.W on CBOE When Trading NASDAQ Global Select Market
15.27USD
21 May 2013
15.27USD
21 May 2013
Price Change (% chg)
$-0.51 (-3.23%)
$-0.51 (-3.23%)
Prev Close
$15.78
$15.78
Open
$15.60
$15.60
Day's High
$15.60
$15.60
Day's Low
$15.19
$15.19
Volume
800
800
Avg. Vol
351
351
52-wk High
$17.18
$17.18
52-wk Low
$10.76
$10.76
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Charles Link |
53 | 2009 | Chairman of the Board, Chief Executive Officer, Chief Scientific Officer |
Nicholas Vahanian |
45 | 2009 | President, Chief Medical Officer |
Gordon Link |
59 | 2008 | Chief Financial Officer |
Brian Wiley |
45 | 2013 | Vice President - Business Development |
Thomas Raffin |
66 | 1999 | Lead Independent Director |
Paul Edick |
58 | 2011 | Independent Director |
Joseph Saluri |
46 | 2010 | Independent Director |
Ernest Talarico |
42 | 1999 | Independent Director |
Lota Zoth |
53 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Charles Link |
Dr. Charles J. Link, Jr., M.D. is Chairman of the Board, Chief Executive Officer, Chief Scientific Officer of NewLink Genetics Corp. He founded NewLink Genetics Corporation in 1999 and has served as Chairman of the company Board of Directors and the company Chief Scientific Officer since inception in 1999. He served as the company President from 2001 to 2009 and has served as the company Chief Executive Officer since 2003. Dr. Link has also served as Chairman and Chief Executive Officer of BioProtection Systems Corporation from 2005 and was its Chief Scientific Officer from 2005 to 2009. Dr. Link has been a practicing oncologist at the Medical Oncology and Hematology Associates of Iowa since 1995. From 1995 to 2003, Dr. Link served as the Director of the John Stoddard Cancer Research Institute, which he co-founded. Dr. Link served as a Medical Oncology Clinical Fellow at the National Cancer Institute, or NCI, National Institutes of Health, or NIH, from 1988 to 1991. Dr. Link attended the U.S. Air Force Academy from 1977 to 1980. Dr. Link holds a B.A. from Stanford University, an M.D. from Stanford University School of Medicine and is certified in Internal Medicine by the American Board of Internal Medicine and has previously been certified in Medical Oncology. |
Nicholas Vahanian |
Dr. Nicholas N. Vahanian, M.D., is President, Chief Medical Officer of NewLink Genetics Corp. He has served as the Company's Chief Medical Officer since 2001, Chief Operations Officer since 2003 and President since 2009. Dr. Vahanian served as a research scientist at the NCI from 1992 to 1994 and at the National Center for Human Genome Research, NIH from 1994 to 1995. He completed his Molecular Oncology Fellowship at the John Stoddard Cancer Research Institute from 1999 to 2000. Dr. Vahanian holds a B.S. in Biology from Virginia Commonwealth University. Dr. Vahanian attended St. Barthalomew's and Royal London Hospital Medical College. He also holds an M.B.A. from the University of Notre Dame. |
Gordon Link |
Mr. Gordon H. Link, Jr., is Chief Financial Officer of NewLink Genetics Corp. Previously, Mr. Link worked for Tapestry Pharmaceuticals, Inc., or Tapestry, as Chief Executive Officer from April to July 2008, Senior Vice President and Chief Financial Officer from 2002 through 2008, President of the Genomics Division from 2000 to 2002 and Vice President and Chief Financial Officer from 1993 to 2002. At Tapestry, Mr. Link directed a staff of five to ten individuals in areas of accounting, cash management, financial planning and analysis, risk management, financial reporting and investor relations. Mr. Link also worked with Tapestry's Board of Directors on financial, business and corporate development matters and coordinated Tapestry's initial public offering and subsequent follow-on public offerings of common stock. On April 4, 2008, the Tapestry Board of Directors appointed Mr. Link as Chief Executive Officer to manage the winding up of Tapestry in bankruptcy. Tapestry filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code on March 19, 2009. Prior to joining Tapestry, Mr. Link served as Corporate Controller of Synergen, Inc., Treasurer of the Syntex-Synergen Neuroscience Joint Venture, Treasurer of Synergen Development Corporation and Audit Manager with Deloitte & Touche USA LLP. Mr. Link received a B.S. from Rensselaer Polytechnic Institute and a B.A. in accounting from Metropolitan State College. |
Brian Wiley |
Mr. Brian Wiley is Vice President - Business Development of NewLink Genetics Corp. Mr. Wiley brings over 20 years of pharmaceutical commercialization and business development experience. Mr. Wiley will focus on securing partnerships in both the U.S. and globally for the company product portfolio. He is also responsible for the commercialization strategy for algenpantucel-L in pancreatic cancer in the U.S. market. Mr. Wiley has held management positions at Celgene Corporation, Gloucester Pharmaceuticals, Millennium/Takeda Pharmaceuticals and Aventis/Sanofi Pharmaceuticals. He played a key role in both the sale of Gloucester Pharmaceuticals to Celgene in 2009 and the acquisition of Abraxis Health by Celgene in 2010. Mr. Wiley has pre-launch and post-approval experience with oncology therapeutics for both solid tumors and hematologic malignancies in the areas of business development, commercial strategy, product launch, marketing, reimbursement, national accounts, sales and sales management. |
Thomas Raffin |
Dr. Thomas A. Raffin, M.D., is Lead Independent Director of NewLink Genetics Corp. Dr. Raffin has spent 30 years on the faculty at Stanford University School of Medicine, where he is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics. Over the past two decades, Dr. Raffin has worked in the healthcare and medical device business sectors and was an advisor to Cell Therapeutics Inc. (1993-1997), Broncus Technologies (1997-2004), iMedica (1998-2002), and Inhale Technologies (1998-2001). He co-founded Rigel Pharmaceuticals, a publicly traded company, in 1996. In 2001, he co-founded Telegraph Hill Partners, a San Francisco life sciences private equity firm as a General Partner. Dr. Raffin has been a director of the following Telegraph Hill Partners private portfolio companies: AngioScore, Confirma, Freedom Innovations, LDR, and PneumRx; and he has worked closely with Estech and Vidacare. Dr. Raffin received a B.A. from Stanford University and an M.D. from Stanford University School of Medicine and did his medical residency at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital) in Boston. |
Paul Edick |
Mr. Paul R. Edick is Independent Director of Newlink Genetics Corp., Since July 29, 2011. Since July 2010, Mr. Edick has been the Chief Executive Officer of Durata Therapeutics, a start-up biopharmaceutical company. From 2008 to 2010, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals, a specialty pharmaceutical company. From 2006 to 2008, Mr. Edick was Chief Executive Officer of MedPointe Healthcare Inc., a specialty pharmaceutical company until its acquisition. From 2002 to 2006, Mr. Edick was President of MedPointe Healthcare Inc. From 1994 to 2002, Mr. Edick worked in a series of positions at G. D. Searle and its acquirer, Pharmacia Corporation, where he led G. D. Searle's U.S. managed care organization from 1994 to 1995, its U.S. marketing organization from 1995 to 1996 and its Global Pain & Inflammation Business from 1996 to 1997. In 1998, Mr. Edick was named G. D. Searle's VP-Canada & Latin America. In 1999, Mr. Edick became President of Asia Pacific, Canada & Latin America. In 2000, upon Pharmacia's acquisition of G. D. Searle, Mr. Edick was named Group Vice President and President, Asia Pacific/Latin America at Pharmacia. From 2008 to 2011, Mr. Edick was a director and from 2009 to 2011 Chairman of the Board of Directors of Life Cycle Pharma, a public technology based biotech located in Copenhagen, Denmark. In addition, Mr. Edick has been a director of Amerita, Inc. since 2006 and was a director of Informed Medical Communications from 2006 to 2011. Mr. Edick holds a B.A. in Psychology from Hamilton College, Clinton. |
Joseph Saluri |
Mr. Joseph Saluri is Independent Director of NewLink Genetics Corp. Mr. Saluri has served as Vice President and General Counsel for Stine Seed Company and its affiliates since July 1999. As part of his duties for Stine, he works to establish collaborative licensing, research and marketing alliances with international biotechnology and agribusiness companies, in addition to managing the legal and intellectual property affairs for the Stine Companies. Previous to his employment with Stine, Mr. Saluri was an attorney and solicitor at law with Nicholas Critelli Associates, PC, in Des Moines and London. Mr. Saluri received a B.S./B.A. from Drake University and a J.D. from Drake University Law School. |
Ernest Talarico |
Mr. Ernest J. Talarico, III, is Independent Director of NewLink Genetics Corp. Mr. Talarico has worked for Mesirow Financial Holdings, Inc., a diversified financial services firm headquartered in Chicago, Illinois since 1998, where he has been a Managing Director since June 2008. Prior to becoming Managing Director, Mr. Talarico served as Senior Vice President from 2005 to 2008, Vice President from 2003 to 2005 and Investment Executive from 1998 to 2003. Mr. Talarico specializes in financial planning and asset allocation, as well as other accumulation and preservation strategies for individuals and businesses. Mr. Talarico sits on several boards and committees, including the Mutual Fund Committee at Mesirow Financial and the Select Advisory Board and Committee at Mesirow Financial. Mr. Talarico has also been the Chairman for the local chapter of the Cystic Fibrosis Foundation and the Founder and Chairman of the Talarico Ataxia Foundation. Mr. Talarico holds a bachelor's degree from the University of Iowa as well as licenses in equities, options and managed futures. |
Lota Zoth |
Ms. Lota S. Zoth CPA., is Independent Director NewLink Genetics Corp., since November 2, 2012. Ms. Zoth served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. from April 2004 to July 2007 and also served as its Controller and Principal Accounting Officer. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporate Controller and Principal Accounting Officer at PSINet Inc., and Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marriott Services, Inc. Ms. Zoth also held senior management positions at Marriott International and PepsiCo, Inc. Ms. Zoth served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth is a member of the Boards of Directors of Orexigen Therapeutics, Inc., Hyperion Therapeutics, Inc., one private company and one non-profit organization. Ms. Zoth received a B.B.A. in accounting, summa cum laude, from Texas Tech University. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Charles Link |
1,452,420 |
Nicholas Vahanian |
958,935 |
Gordon Link |
536,616 |
Brian Wiley |
-- |
Thomas Raffin |
-- |
Paul Edick |
-- |
Joseph Saluri |
-- |
Ernest Talarico |
-- |
Lota Zoth |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Charles Link |
0 | 0 |
Nicholas Vahanian |
0 | 0 |
Gordon Link |
0 | 0 |
Brian Wiley |
0 | 0 |
Thomas Raffin |
0 | 0 |
Paul Edick |
0 | 0 |
Joseph Saluri |
0 | 0 |
Ernest Talarico |
0 | 0 |
Lota Zoth |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
LINK CHARLES J JR |
35,000 | $14.96 |
LINK GORDON HAROLD JR |
3,200 | $2.10 |
LINK CHARLES J JR |
40,000 | $14.58 |
LINK GORDON HAROLD JR |
2,741 | $14.65 |
LINK GORDON HAROLD JR |
459 | $14.65 |
LINK CHARLES J JR |
15,000 | $11.74 |
LINK CHARLES J JR |
5,000 | $11.92 |
LINK CHARLES J JR |
55,000 | $11.99 |
STINE SEED FARM INC |
880,000 | $11.40 |
LINK GORDON HAROLD JR |
1,000 | $2.10 |
LINK GORDON HAROLD JR |
826 | $12.10 |
LINK GORDON HAROLD JR |
174 | $12.10 |
LINK CHARLES J JR |
25,000 | $12.50 |
LINK GORDON HAROLD JR |
832 | $12.53 |
LINK GORDON HAROLD JR |
1,000 | $2.10 |
LINK GORDON HAROLD JR |
168 | $12.53 |
LINK GORDON HAROLD JR |
153 | $13.77 |
LINK GORDON HAROLD JR |
847 | $13.77 |
LINK GORDON HAROLD JR |
1,000 | $2.10 |
LINK GORDON HAROLD JR |
779 | $14.84 |
LINK GORDON HAROLD JR |
4,721 | $14.84 |
LINK GORDON HAROLD JR |
5,500 | $2.10 |
TALARICO ERNEST III |
2,380 | $0.53 |
VAHANIAN NICHOLAS N |
17,623 | $4.20 |
VAHANIAN NICHOLAS N |
12,772 | $2.10 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
